Clinical trial · Observational
Exploring Compensation to Maintain Cognitive Function in Adults Newly Diagnosed With Brain Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Recent research indicates that variability in cognitive function for brain tumor survivors may be explained by differences in cognitive reserve (CR) and use of compensatory strategies.However, it is unknown when cognitive function declines or survivors tap into compensation. This longitudinal mixed methods study proposes to explore differences in cognitive function and change over time in newly diagnosed adults with brain cancer prior to, immediately after (within 2 weeks), and 2-3 months after radiation therapy treatment has been completed. Specific aims are to: Aim1: Examine the relationship between objective and subjective cognitive function in subjects newly diagnosed with brain cancer prior to and after XRT. Aim 2: Explore the interrelationship between cognitive function and compensation (neural and behavioral) by high/low CR prior to and after XRT. Aim 3: Describe the trajectory of objective and subjective cognitive function over time by CR, cancer type, and associated treatment-related factors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases, Adult | Brain Neoplasm | PROBABILISTIC | 0.70 |
| Primary Brain Tumor | Primary Brain Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neuropsychological Testing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single arm study
- description
- In this feasibility study, longitudinal mixed methods will be used to measure cognitive function and symptoms by objective tests, interviews, and biomarker assay in adults with brain cancer over time: prior to radiation (XRT; T1), 2-weeks post-XRT (T2), 2-3 months post-XRT (T3).
- interventionNames
- Other: Neuropsychological Testing
Primary outcomes (3)
- measure
- Change in cognitive function
- timeFrame
- Baseline, 2 weeks and 3 months post radiation therapy
- description
- Serial neurocognitive testing using composite scores from the Trail Making A and B test
- measure
- Change in cognitive function
- timeFrame
- Baseline, 2 weeks and 3 months post radiation therapy
- description
- Serial neurocognitive testing using composite scores from the Controlled Oral Word Association (COWA) test
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 30-65 years, * Newly diagnosed with primary brain tumor or secondary brain metastases * Able to read and write English as the neurocognitive testing will be administered using English language forms Exclusion Criteria: * Those with \>moderate cognitive impairment (Mini-Mental Status Examination \[MMSE\] score\<24) at baseline * Aphasia * Other neurodegenerative disorders Drink 3 or more alcoholic beverages per day (per Centers for Disease Control definition), report current use of illicit drugs/misuse of prescription medication, or currently undergoing treatment or had previous treatment for substance abuse at any time period (alcoholism or drug abuse).
References
Publications (0)
Data not yet available